— Data demonstrate the potential of WU-NK-101 to reverse primary and acquired mechanisms of immune checkpoint blockade (ICB) resistance —
ST. LOUIS, MO and SAN DIEGO, CA, March 29, 2023 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced an upcoming presentation highlighting WU-NK-101, the company’s lead memory natural killer (NK) cell therapy product. The data support the potential of WU-NK-101 to overcome resistance to immune checkpoint blockade (ICB) therapy and will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place April 14 – 19, 2023 in Orlando, Florida.
The details of Wugen’s presentation at AACR are as follows:
Title: WU-NK-101 as Salvage Therapy Post Immune Checkpoint Blockade (ICB)
Session: Immunotherapy Strategies and Mechanisms
Session Date and Time: Wednesday, April 19, 2023, 9:00 a.m. – 12:30 p.m. ET
Location: Section 25
Poster Number: 5
Abstract Number: 6418
Presenter: Tom Leedom
Additional meeting information can be found at https://www.aacr.org/meeting/aacr-annual-meeting-2023/.
About WU-NK-101
WU-NK-101 is a novel immunotherapy harnessing the power of memory natural killer (NK) cells to treat liquid and solid tumors. Memory NK cells are hyper-functional, long-lasting immune cells that exhibit enhanced anti-tumor activity and a cytokine-induced memory-like (CIML) phenotype. This rare cell population has a superior phenotype, proliferation capacity, and metabolic fitness that makes it better suited for cancer therapy than other NK cell therapies. Wugen is applying its proprietary MonetaTM platform to advance WU-NK-101 as a commercially scalable, off-the-shelf cell therapy for cancer. WU-NK-101 is currently in development for acute myelogenous leukemia (AML) and solid tumors.
About Wugen
Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary MonetaTM platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit www.wugen.com.
Investor Contact:
Elsie Yau, Stern Investor Relations, Inc.
212-698-8700
elsie.yau@sternir.com
